Novo Nordisk submitted a supplemental New Drug Application (NDA) to the FDA in November, and under the CNPV program, a review decision is usually expected within one to two months after the filing is accepted.
Global pharmaceutical company Eli Lilly (NYSE:LLY) reported Q4 CY2025 results exceeding the market’s revenue expectations, with sales up 42.6% year on year to $19.29 billion. The company’s full-year revenue guidance of $81.5 billion at the midpoint came in 5.1% above analysts’ estimates. Its non-GAAP profit of $7.54 per share was 8.7% above analysts’ consensus estimates.
Novo Nordisk dropped after management forecasts weaker 2026 growth, shifting attention from recent results to pricing pressure and rising competition in obesity treatments.
Novo Nordisk stock sank as management forecasts decelerating growth in 2026. But should you treat this selloff in NVO shares as a buying opportunity? Let’s find out.
As the pharmaceutical industry enters the heart of its Q4 2025 earnings season this February 2, 2026, a clear divide has emerged between the high-flying giants of the metabolic gold rush and those struggling to navigate the steepest regulatory and patent hurdles in a generation. With major reports from Eli
As of early 2026, the promise of “digital-first” drug discovery has shifted from a speculative horizon to a tangible industrial reality. Since its groundbreaking release in May 2024, AlphaFold 3 (AF3)—the generative AI model developed by Google DeepMind and its commercial sibling, Isomorphic Labs—has fundamentally transformed the landscape of molecular biology. By expanding beyond simple [...]
Markets enter February following a volatile final trading day of January that saw investors grappling with hotter-than-expected inflation data alongside news of a new Federal Reserve chair nominee.
